200 related articles for article (PubMed ID: 29061764)
1. The Structural Basis for Complement Inhibition by Gigastasin, a Protease Inhibitor from the Giant Amazon Leech.
Pang SS; Wijeyewickrema LC; Hor L; Tan S; Lameignere E; Conway EM; Blom AM; Mohlin FC; Liu X; Payne RJ; Whisstock JC; Pike RN
J Immunol; 2017 Dec; 199(11):3883-3891. PubMed ID: 29061764
[TBL] [Abstract][Full Text] [Related]
2. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2.
Keizer MP; Pouw RB; Kamp AM; Patiwael S; Marsman G; Hart MH; Zeerleder S; Kuijpers TW; Wouters D
Eur J Immunol; 2015 Feb; 45(2):544-50. PubMed ID: 25359215
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor.
Kerr FK; Thomas AR; Wijeyewickrema LC; Whisstock JC; Boyd SE; Kaiserman D; Matthews AY; Bird PI; Thielens NM; Rossi V; Pike RN
Mol Immunol; 2008 Feb; 45(3):670-7. PubMed ID: 17709141
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation.
Kocsis A; Kékesi KA; Szász R; Végh BM; Balczer J; Dobó J; Závodszky P; Gál P; Pál G
J Immunol; 2010 Oct; 185(7):4169-78. PubMed ID: 20817870
[TBL] [Abstract][Full Text] [Related]
5. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity.
Dobó J; Harmat V; Beinrohr L; Sebestyén E; Závodszky P; Gál P
J Immunol; 2009 Jul; 183(2):1207-14. PubMed ID: 19564340
[TBL] [Abstract][Full Text] [Related]
6. Distinction of early complement classical and lectin pathway activation
Hurler L; Toonen EJM; Kajdácsi E; van Bree B; Brandwijk RJMGE; de Bruin W; Lyons PA; Bergamaschi L; ; Sinkovits G; Cervenak L; Würzner R; Prohászka Z
Front Immunol; 2022; 13():1039765. PubMed ID: 36420270
[TBL] [Abstract][Full Text] [Related]
7. Molecular Interactions Required for Activation of Complement Component C2 Include Exosites Located on the Serine Protease Domain of C1s and Mannose-Binding Lectin Associated Protease-2.
Hor L; Pan J; Pike RN; Wijeyewickrema LC
J Immunol; 2024 Apr; 212(7):1172-1177. PubMed ID: 38372634
[TBL] [Abstract][Full Text] [Related]
8. Paths reunited: Initiation of the classical and lectin pathways of complement activation.
Wallis R; Mitchell DA; Schmid R; Schwaeble WJ; Keeble AH
Immunobiology; 2010; 215(1):1-11. PubMed ID: 19783065
[TBL] [Abstract][Full Text] [Related]
9. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments.
Ambrus G; Gál P; Kojima M; Szilágyi K; Balczer J; Antal J; Gráf L; Laich A; Moffatt BE; Schwaeble W; Sim RB; Závodszky P
J Immunol; 2003 Feb; 170(3):1374-82. PubMed ID: 12538697
[TBL] [Abstract][Full Text] [Related]
10. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
11. Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors.
Szakács D; Kocsis A; Szász R; Gál P; Pál G
J Biol Chem; 2019 May; 294(20):8227-8237. PubMed ID: 30952698
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2.
Rossi V; Cseh S; Bally I; Thielens NM; Jensenius JC; Arlaud GJ
J Biol Chem; 2001 Nov; 276(44):40880-7. PubMed ID: 11527969
[TBL] [Abstract][Full Text] [Related]
13. The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.
Schwaeble W; Dahl MR; Thiel S; Stover C; Jensenius JC
Immunobiology; 2002 Sep; 205(4-5):455-66. PubMed ID: 12396007
[TBL] [Abstract][Full Text] [Related]
14. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not.
Paréj K; Dobó J; Závodszky P; Gál P
Mol Immunol; 2013 Jul; 54(3-4):415-22. PubMed ID: 23399388
[TBL] [Abstract][Full Text] [Related]
15. Assembly of C1 and the MBL- and ficolin-MASP complexes: structural insights.
Gaboriaud C; Teillet F; Gregory LA; Thielens NM; Arlaud GJ
Immunobiology; 2007; 212(4-5):279-88. PubMed ID: 17544813
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of complement proteases C1s/mannan-binding lectin-associated serine protease-2 (MASP-2) chimeras reveals the higher C4 recognition efficacy of the MASP-2 complement control protein modules.
Rossi V; Teillet F; Thielens NM; Bally I; Arlaud GJ
J Biol Chem; 2005 Dec; 280(51):41811-8. PubMed ID: 16227207
[TBL] [Abstract][Full Text] [Related]
17. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function.
Degn SE; Jensen L; Hansen AG; Duman D; Tekin M; Jensenius JC; Thiel S
J Immunol; 2012 Oct; 189(8):3957-69. PubMed ID: 22966085
[TBL] [Abstract][Full Text] [Related]
18. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis.
Ferreira VP; Fazito Vale V; Pangburn MK; Abdeladhim M; Mendes-Sousa AF; Coutinho-Abreu IV; Rasouli M; Brandt EA; Meneses C; Lima KF; Nascimento Araújo R; Pereira MH; Kotsyfakis M; Oliveira F; Kamhawi S; Ribeiro JM; Gontijo NF; Collin N; Valenzuela JG
Sci Rep; 2016 Jan; 6():19300. PubMed ID: 26758086
[TBL] [Abstract][Full Text] [Related]
19. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation.
Hair PS; Gronemus JQ; Crawford KB; Salvi VP; Cunnion KM; Thielens NM; Arlaud GJ; Rawal N; Krishna NK
Mol Immunol; 2010 Jan; 47(4):792-8. PubMed ID: 19896716
[TBL] [Abstract][Full Text] [Related]
20. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation.
Beinrohr L; Dobó J; Závodszky P; Gál P
Trends Mol Med; 2008 Dec; 14(12):511-21. PubMed ID: 18977695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
